Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on February 2, 2004

Circulation. 2004
Published online before print February 2, 2004, doi: 10.1161/01.CIR.0000112606.41127.D2
A more recent version of this article appeared on February 24, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/7/926    most recent
01.CIR.0000112606.41127.D2v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menegazzi, J. J.
Right arrow Articles by Logue, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menegazzi, J. J.
Right arrow Articles by Logue, E. S.
Related Collections
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow CPR and emergency cardiac care
Right arrow Arrhythmias, clinical electrophysiology, drugs

Submitted on February 27, 2003
Revised on October 13, 2003
Accepted on October 14, 2003

Ventricular Fibrillation Scaling Exponent Can Guide Timing of Defibrillation and Other Therapies

James J. Menegazzi PhD*, Clifton W. Callaway MD, PhD, Lawrence D. Sherman MD, David P. Hostler PhD, Henry E. Wang MD, Kristofer C. Fertig BS, and Eric S. Logue BS

From the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa.

* To whom correspondence should be addressed. E-mail: menegazz+{at}pitt.edu.

Background--The scaling exponent (ScE) of the ventricular fibrillation (VF) waveform correlates with duration of VF and predicts defibrillation outcome. We compared 4 therapeutic approaches to the treatment of VF of various durations.

Methods and Results--Seventy-two swine (19.5 to 25.7 kg) were randomly assigned to 1 of 9 groups (n=8 each). VF was induced and left untreated until the ScE reached 1.10, 1.20, 1.30, or 1.40. Animals were treated with either immediate countershock (IC); 3 minutes of CPR before the first countershock (CPR); CPR for 2 minutes, then drugs given with 3 more minutes of CPR before the first shock (CPR-D); or drugs given at the start of CPR with 3 minutes of CPR before the first shock (Drugs+CPR). Return of spontaneous circulation (ROSC) and 1-hour survival were analyzed with {chi}2 and Kaplan-Meier survival curves. IC was effective when the ScE was low but had decreasing success as the ScE increased. No animals in the 1.30 or 1.40 groups had ROSC from IC (0 of 16). CPR did not improve first shock outcome in the 1.20 CPR group (3 of 8 ROSC). Kaplan-Meier survival analyses indicated that IC significantly delayed time to ROSC in both the 1.3 (P=0.0006) and the 1.4 (P=0.005) groups.

Conclusions--VF of brief to moderate duration is effectively treated by IC. When VF is prolonged, as indicated by an ScE of 1.3 or greater, IC was not effective and delayed time to ROSC. The ScE can help in choosing the first intervention in the treatment of VF.


Key words: fibrillation • heart arrest • defibrillation • cardiopulmonary resuscitation




This article has been cited by other articles:


Home page
EuropaceHome page
N. A. Lever, E. G. Newall, and P. D. Larsen
Differences in the characteristics of induced and spontaneous episodes of ventricular fibrillation
Europace, November 1, 2007; 9(11): 1054 - 1058.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. F. Huizar, M. D. Warren, A. G. Shvedko, J. Kalifa, J. Moreno, S. Mironov, J. Jalife, and A. V. Zaitsev
Three distinct phases of VF during global ischemia in the isolated blood-perfused pig heart
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1617 - H1628.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J.-q. Zhong, G. Laurent, P. P.-S. So, Xudong Hu, J. K. Hennan, and P. Dorian
Effects of Rotigaptide, a Gap Junction Modifier, on Defibrillation Energy and Resuscitation From Cardiac Arrest in Rabbits
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 69 - 77.
[Abstract] [PDF]


Home page
CirculationHome page
Part 5: Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing
Circulation, December 13, 2005; 112(24_suppl): IV-35 - IV-46.
[Full Text] [PDF]


Home page
NEJMHome page
K. A. Marill and P. T. Ellinor
Case 37-2005 -- A 35-Year-Old Man with Cardiac Arrest while Sleeping
N. Engl. J. Med., December 8, 2005; 353(23): 2492 - 2501.
[Full Text] [PDF]


Home page
CirculationHome page
Part 3: Defibrillation
Circulation, November 29, 2005; 112(22_suppl): III-17 - III-24.
[Full Text] [PDF]